参考文献

［1］FRANCIS J M, Beck Jr L H, SALANT D J. Membranous nephropathy: a journey from bench to bedside [J]. Am J Kidney Dis, 2016, 68 (1): 138-147.

［2］XU X, WANG G B, LU T, et al. Long-term exposure to air pollution and increased risk of membranous nephropathy in China [J]. J Am Soc Nephrol, 2016, 27 (12):3739-3746.

［3］Gupta S, Köttgen A, Hoxha E, et al. Genetics of membranous nephropathy [J]. Nephrol Dial Transplant, 2018, 33(9): 1493-1502.

［4］LE WB, SHI J S, ZHANG T et al. HLA-DRB1*15: 01 and HLA-DRB3*02: 02 in PLA2R-related membranous nephropathy [J]. J Am Soc Nephrol, 2017, 28 (5): 1642-1650.

［5］TOMAS N M, BECK JR L H, MEYER-SCHWESINGER C, et al. Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy [J]. N Engl J Med, 2014, 371 (24): 2277-2287.

［6］LARSEN C P, MESSIAS N C, SILVA F G, et al. Determination of primary versus secondarymembranous glomerulopathy utilizing phospholipase A2 receptor staining in renal biopsies [J]. Mod Pathol, 2013, 26 (5):709-715.

［7］DE VRIESE A S, GLASSOCK R J, NATH K A, et al. A proposal for a serology-based approach to membranous nephropathy [J]. J Am Soc Nephrol, 2017, 28 (2): 421-430.

［8］HOXHA E, WIECH T, STAHL P R, et al. A mechanism for cancer-associated membranous nephropathy [J]. N Engl J Med, 2016, 374 (20): 1995-1996.

［9］ZOU R, LIU G, CUI Z, et al. Clinical and immunologic characteristics of patients with anca-associated glomerulonephritis combined with membranous nephropathy: a retrospective cohort study in a single Chinese center [J]. Medicine (Baltimore), 2015, 94 (37): e1472.

［10］RODRIGUEZ E F, NASR S H, LARSEN C P, et al. Membranous nephropathy with crescents: a series of 19 cases [J]. Am J Kidney Dis, 2014, 64 (1): 66-73.

［11］NA W, YI K, SONG Y S, et al. Dissecting the relationships of IgG subclasses and complements in membranous lupus nephritis and idiopathic membranous nephropathy [J]. PLoS One, 2017, 12 (3): e0174501.

［12］RADICE A, PIERUZZI F, TREZZI B, et al. Diagnostic specificity of autoantibodies to M-type phospholipase A2 receptor (PLA2R) in differentiating idiopathic membranous nephropathy (IMN) from secondary forms and other glomerular diseases [J]. J Nephrol, 2018, 31 (2):271-278.

［13］POZDZIK A, TOUZANI F, BROCHÉRIOU I. Molecular classification of membranous nephropathy [J]. Curr Opin Nephrol Hypertens, 2019, 28 (4): 336-344.

［14］HOFSTRA J M, FERVENZA F C, WETZElS J F. Treatment of idiopathic membranous nephropathy [J]. Nat Rev Nephrol, 2013, 9 (8): 443-458.

［15］FERVENZA F C, APPEL G B, BARBOUR S J, et al. Rituximab or cyclosporine in the treatment of membranous nephropathy [J]. N Engl J Med, 2019, 381 (1): 36-46.

［16］Kidney Disease: Improving Global Outcomes(KDIGO) Glomerulonephritis Work Group. KDIGO clinical practice guideline for glomerulonephritis [J]. Kidney Int Suppl, 2020: 133.